Burning Rock Biotech Limited Reports Q1 2025 Financial Results and Advances in Oncology Research

Burning Rock Biotech (BNR) reported a 5.9% year-over-year increase in Q1 2025 revenue, reaching RMB133.1 million (US$18.3 million), driven by growth in its in-hospital business and a nearly 80% surge in pharma R&D service revenue. The company highlighted progress with its CanCatch® Custom MRD product and presented findings at cancer conferences, while gross profit margin improved to 73.2%; however, the company still reported a net loss of RMB13.5 million (US$1.9 million) despite a 46.8% decrease in operating expenses and a cash position of RMB497.4 million (US$68.5 million) as of March 31, 2025.

Analysis

Burning Rock Biotech Limited (BNR) reported Q1 2025 revenues of RMB133.1 million (US$18.3 million), a 5.9% year-over-year increase, primarily driven by a substantial 79.9% surge in pharma research and development services revenue to RMB37.1 million and a modest 0.5% growth in its in-hospital business to RMB57.7 million. This growth in core areas was partially offset by a 19.6% decline in revenue from the central laboratory business, which fell to RMB38.3 million as the company strategically focuses on its in-hospital segment. Gross profit improved significantly by 13.7% year-over-year to RMB97.4 million, with the gross profit margin expanding from 68.2% to 73.2%, reflecting enhanced operational efficiency and cost optimization across all channels. Operating expenses saw a notable decrease of 46.8% to RMB112.6 million, attributed to budget control measures and headcount reductions. Consequently, the net loss for the quarter was substantially reduced to RMB13.5 million (US$1.9 million) from RMB121.5 million in Q1 2024. The company maintained a cash position of RMB497.4 million (US$68.5 million) as of March 31, 2025. Key operational highlights include advancements with its CanCatch® Custom MRD product for esophageal squamous cell carcinoma and promising study results for lung cancer and gastrointestinal stromal tumor assays presented at major oncology conferences. Despite these positive developments, the company remains loss-making. Institutional sentiment, as per the latest available data from Q4 2024, showed one institution decreasing its position, with HSG HOLDING LTD divesting its entire stake.

Key Decisions for Investors

• Investors should acknowledge the positive trajectory in revenue growth driven by pharma R&D and in-hospital segments, alongside significant gross margin improvement and drastic operating expense reduction, but remain cautious due to the persistent net loss.
• Monitor the continued growth and margin sustainability in the pharma R&D and in-hospital channels, as these are pivotal to offsetting the declining central laboratory business and achieving overall profitability.
• Consider the clinical advancements with products like CanCatch® Custom as potential long-term value drivers, while also noting the recent (Q4 2024) institutional selling as a factor for risk assessment.
• Evaluate the company's ability to sustain cost control measures without hindering future growth initiatives and product development, particularly given the competitive landscape of precision oncology.